



ANMCO

ASSOCIAZIONE NAZIONALE MEDICI CARDIOLOGI OSPEDALIERI

Via La Marmora, 36 – 50121 Firenze
<http://www.anmco.it> e-mail: segreteria@anmco.it
Tel. +39 055 51011 - Fax +39 055 5101350

Corso ANMCO di Formazione a Distanza

AMILOIDOSI & FABRY

1° Parte

Piano Formativo 2020-2021

6 luglio 2020 - 30 aprile 2021

APPROFONDIMENTI BIBLIOGRAFICI SU AMILOIDOSI & FABRY

MODULO I

EPIDEMIOLOGIA, EZIOLOGIA E CLINICA DELLA IPERTROFIA VENTRICOLARE SINISTRA E DELL'AMILOIDOSI

Borlaug BA. **Heart failure with preserved and reduced ejection fraction: different risk profiles for different diseases.** Eur Heart J. 2013; 34: 1393-5.

González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. **Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.** Eur Heart J. 2015; 36: 2585-94.

González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-Del Moral FJ, Milandri A, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P. **Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.** Eur Heart J. 2017; 38: 1895-1904.

Damy T, Costes B, Hagège AA, Donal E, Eicher JC, Slama M, Guellich A, Rappeneau S, Gueffet JP, Logeart D, Planté-Bordeneuve V, Bouvaist H, Huttin O, Mulak G, Dubois-Randé JL, Goossens M, Canoui-Poitaine F, Buxbaum JN. **Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.** Eur Heart J. 2016; 37: 1826-34.



ANMCO

ASSOCIAZIONE NAZIONALE MEDICI CARDIOLOGI OSPEDALIERI

Via La Marmora, 36 – 50121 Firenze
<http://www.anmco.it> e-mail: segreteria@anmco.it
Tel. +39 055 51011 - Fax +39 055 5101350

MODULO II

EPIDEMIOLOGIA, EZIOLOGIA E CLINICA DELLA IPERTROFIA VENTRICOLARE SINISTRA E DELLA MALATTIA DI ANDERSON-FABRY

Meikle PJ, Hopwood JJ, Clague AE, Carey WF. **Prevalence of lysosomal storage disorders.** JAMA 1999; 281: 249-54.

MODULO III

L'IMAGING DELLA IPERTROFIA VENTRICOLARE SINISTRA NELL'AMILOIDOSI: DALL'ECO ALLA RISONANZA

Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Heliö T, Linhart A, Mogensen J, Pinto Y, Ristic A, Seggewiss H, Sinagra G, Tavazzi L, Elliott PM. **Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases.** Eur Heart J. 2013; 34: 1448-58.

Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S. **Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.** Eur Heart J. 2013; 34: 520-8.

Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH. **Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.** Circulation. 2014; 129: 1840-9.

MODULO IV

ITER DIAGNOSTICO E DIAGNOSI DIFFERENZIALE

Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. **Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.** JAMA 2017; 318: 962-963.